Taek-Joo Lim

Title: Taek-Joo Lim: Innovator in Pharmaceutical Composition

Introduction

Taek-Joo Lim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of hyperlipidemia and hypertriglyceridemia. With a total of 2 patents, his work is recognized for its innovative approach to addressing these health issues.

Latest Patents

Lim's latest patents include a pharmaceutical composition for preventing or treating hyperlipidemia. This composition comprises (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt, along with an angiotensin II receptor blocker as active ingredients. Another notable patent is a method for treating hypertriglyceridemia, which includes the same oxazolidinone compound and amlodipine or its pharmaceutically acceptable salt at a synergistic ratio of about 4:1.

Career Highlights

Taek-Joo Lim is currently associated with Daewoong Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work has been instrumental in developing effective treatments for lipid-related health conditions.

Collaborations

Lim has collaborated with notable colleagues, including Jong-Wook Lee and Sang-Ho Lee, contributing to the advancement of pharmaceutical research and development.

Conclusion

Taek-Joo Lim's contributions to pharmaceutical innovations highlight his commitment to improving health outcomes through effective treatments. His patents reflect a deep understanding of complex medical conditions and a dedication to advancing medical science.